Grifols
Grifols, officially known as Grifols, S.A., is a global leader in the biopharmaceutical industry, headquartered in Barcelona, Spain. Founded in 1940, the company has established a strong presence in key operational regions, including Europe, North America, and Latin America. Grifols specialises in the development, production, and distribution of plasma-derived medicines, diagnostic solutions, and hospital products, making significant contributions to healthcare. With a commitment to innovation, Grifols has achieved notable milestones, including advancements in immunoglobulin therapies and the establishment of a robust network of plasma collection centres. The company is recognised for its high-quality products, such as albumin and clotting factor concentrates, which are essential for treating various medical conditions. Grifols continues to solidify its market position through strategic partnerships and a focus on research and development, underscoring its dedication to improving patient outcomes worldwide.
DitchCarbon Score
How does Grifols's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Grifols's score of 52 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Grifols's reported carbon emissions
In 2023, Grifols reported total greenhouse gas emissions of approximately 1.1 million tonnes CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions accounted for about 106.5 million tonnes CO2e, while Scope 2 emissions were approximately 98.1 million tonnes CO2e. Scope 3 emissions, which include indirect emissions from the supply chain, totalled around 947.5 million tonnes CO2e. Grifols has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2022 as the baseline year. Additionally, the company targets a 25% reduction in absolute Scope 3 emissions from categories such as purchased goods and services, capital goods, and upstream transportation and distribution within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to global efforts to limit temperature rise to 1.5°C. Overall, Grifols is actively working towards significant emissions reductions, demonstrating a commitment to sustainability within the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 147,669,000 | 000,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 117,152,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 44,733,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Grifols is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
